SK Chemicals announced that its copromotion agreement with Lilly Korea for the antidepressant Cymbalta Cap (duloxetine hydrochloride) and the migraine treatment Emgality (galcanezumab-gnlm) has been brought to an end.

Cymbalta is the number one selling antidepressant on the market. Sales of Emgality have also been rising since last year's reimbursement approval.

SK Chemicals has co-marketed Cymbalta since 2017 and Emgality since July 2020 with Lilly.

According to industry sources, SK Chemicals will supply Cymbalta until Dec. 31 last year and Emgality until Jan. 31 this year with the termination of the co-promotion agreement with Lilly Korea.

Cymbalta is the